{"groups":[{"description":"Patients receive pralatrexate 20mg/m2 IV over 3-5 minutes on days 1 and 8 and pembrolizumab 200mg IV over 30 minutes on day 1. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.","id":"FG000","title":"Phase I - Dose Level 1: Pembrolizumab 200mg + Pralatrexate 20mg/m2"},{"description":"Patients receive pralatrexate 30mg/m2 IV over 3-5 minutes on days 1 and 8 and pembrolizumab 200mg IV over 30 minutes on day 1. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.","id":"FG001","title":"Phase I - Dose Level 2: Pembrolizumab 200mg + Pralatrexate 30mg/m2"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"6"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"6"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Due to low/slow accrual, this study was permanently closed to accrual after enrolling 13 patients in Phase I, with no accrual in Phase II. Of the 13 patients in Phase I, 7 were at dose level 1 and 6 were at dose level 2."}